DOCSLIB.ORG

Mouse Gnmt Knockout Project (CRISPR/Cas9)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Mouse Gnmt Knockout Project (CRISPR/Cas9) https://www.alphaknockout.com Mouse Gnmt Knockout Project (CRISPR/Cas9) Objective: To create a Gnmt knockout Mouse model (C57BL/6N) by CRISPR/Cas-mediated genome engineering. Strategy summary: The Gnmt gene (NCBI Reference Sequence: NM_010321 ; Ensembl: ENSMUSG00000002769 ) is located on Mouse chromosome 17. 6 exons are identified, with the ATG start codon in exon 1 and the TGA stop codon in exon 6 (Transcript: ENSMUST00000002846). Exon 2 will be selected as target site. Cas9 and gRNA will be co-injected into fertilized eggs for KO Mouse production. The pups will be genotyped by PCR followed by sequencing analysis. Note: Mice homozygous for a null mutation display elevated levels of methionine and S-adenosylmethionine in the liver. Mice homozygous for another null allele exhibit hepatitis, increased hepatic glycogen storage, and hepatocellular carcinoma. Exon 2 starts from about 23.55% of the coding region. Exon 2 covers 14.56% of the coding region. The size of effective KO region: ~128 bp. The KO region does not have any other known gene. Page 1 of 8 https://www.alphaknockout.com Overview of the Targeting Strategy Wildtype allele 5' gRNA region gRNA region 3' 1 2 6 Legends Exon of mouse Gnmt Knockout region Page 2 of 8 https://www.alphaknockout.com Overview of the Dot Plot (up) Window size: 15 bp Forward Reverse Complement Sequence 12 Note: The 1553 bp section upstream of Exon 2 is aligned with itself to determine if there are tandem repeats. Tandem repeats are found in the dot plot matrix. The gRNA site is selected outside of these tandem repeats. Overview of the Dot Plot (down) Window size: 15 bp Forward Reverse Complement Sequence 12 Note: The 548 bp section downstream of Exon 2 is aligned with itself to determine if there are tandem repeats. No significant tandem repeat is found in the dot plot matrix. So this region is suitable for PCR screening or sequencing analysis. Page 3 of 8 https://www.alphaknockout.com Overview of the GC Content Distribution (up) Window size: 300 bp Sequence 12 Summary: Full Length(1553bp) | A(27.5% 427) | C(22.99% 357) | T(24.21% 376) | G(25.31% 393) Note: The 1553 bp section upstream of Exon 2 is analyzed to determine the GC content. No significant high GC-content region is found. So this region is suitable for PCR screening or sequencing analysis. Overview of the GC Content Distribution (down) Window size: 300 bp Sequence 12 Summary: Full Length(548bp) | A(18.61% 102) | C(28.1% 154) | T(29.01% 159) | G(24.27% 133) Note: The 548 bp section downstream of Exon 2 is analyzed to determine the GC content. No significant high GC-content region is found. So this region is suitable for PCR screening or sequencing analysis. Page 4 of 8 https://www.alphaknockout.com BLAT Search Results (up) QUERY SCORE START END QSIZE IDENTITY CHROM STRAND START END SPAN ----------------------------------------------------------------------------------------------- browser details YourSeq 1553 1 1553 1553 100.0% chr17 - 46727393 46728945 1553 browser details YourSeq 235 1064 1393 1553 94.5% chr2 + 130670414 130779345 108932 browser details YourSeq 220 1066 1390 1553 97.9% chr17 + 53619522 53620018 497 browser details YourSeq 212 1088 1390 1553 95.8% chr2 - 32101876 32102201 326 browser details YourSeq 210 1097 1390 1553 97.4% chr17 - 32261386 32261709 324 browser details YourSeq 208 830 1390 1553 90.7% chr17 - 56243546 56244017 472 browser details YourSeq 208 1082 1391 1553 94.1% chr16 + 14322552 14323132 581 browser details YourSeq 207 1065 1390 1553 91.3% chr2 - 70997981 70998216 236 browser details YourSeq 206 1083 1392 1553 93.7% chr4 + 129296501 129297126 626 browser details YourSeq 204 1089 1390 1553 95.2% chr4 + 116680871 116681231 361 browser details YourSeq 203 830 1389 1553 93.4% chr17 - 24098897 24099407 511 browser details YourSeq 200 1169 1391 1553 96.2% chr1 + 78415614 78415831 218 browser details YourSeq 199 832 1392 1553 93.4% chr6 - 100164861 100165395 535 browser details YourSeq 198 1194 1405 1553 98.1% chr11 + 23259838 23260050 213 browser details YourSeq 196 1197 1406 1553 98.6% chr6 - 54651256 54651470 215 browser details YourSeq 195 1134 1390 1553 97.2% chr11 - 101428001 101428334 334 browser details YourSeq 195 1193 1404 1553 97.6% chr2 + 103818241 103818456 216 browser details YourSeq 195 1106 1390 1553 96.3% chr12 + 8768094 8768536 443 browser details YourSeq 194 1195 1404 1553 98.1% chr7 - 54320853 54321068 216 browser details YourSeq 193 1201 1406 1553 97.1% chr7 - 101254271 101254478 208 Note: The 1553 bp section upstream of Exon 2 is BLAT searched against the genome. No significant similarity is found. BLAT Search Results (down) QUERY SCORE START END QSIZE IDENTITY CHROM STRAND START END SPAN ----------------------------------------------------------------------------------------------- browser details YourSeq 548 1 548 548 100.0% chr17 - 46726717 46727264 548 browser details YourSeq 26 177 206 548 81.5% chr16 - 4492908 4492934 27 browser details YourSeq 25 518 543 548 100.0% chr11 - 81079904 81079936 33 browser details YourSeq 23 525 548 548 100.0% chr11 + 19647766 19647790 25 browser details YourSeq 22 190 211 548 100.0% chr14 + 122169697 122169718 22 browser details YourSeq 21 114 134 548 100.0% chr17 + 79422978 79422998 21 browser details YourSeq 20 520 539 548 100.0% chr13 - 42238235 42238254 20 browser details YourSeq 20 7 26 548 100.0% chr11 + 102375177 102375196 20 Note: The 548 bp section downstream of Exon 2 is BLAT searched against the genome. No significant similarity is found. Page 5 of 8 https://www.alphaknockout.com Gene and protein information: Gnmt glycine N-methyltransferase [ Mus musculus (house mouse) ] Gene ID: 14711, updated on 5-Oct-2019 Gene summary Official Symbol Gnmt provided by MGI Official Full Name glycine N-methyltransferase provided by MGI Primary source MGI:MGI:1202304 See related Ensembl:ENSMUSG00000002769 Gene type protein coding RefSeq status VALIDATED Organism Mus musculus Lineage Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae; Murinae; Mus; Mus Expression Restricted expression toward liver adult (RPKM 1724.9) See more Orthologs human all Genomic context Location: 17 22.9 cM; 17 C See Gnmt in Genome Data Viewer Exon count: 6 Annotation release Status Assembly Chr Location 108 current GRCm38.p6 (GCF_000001635.26) 17 NC_000083.6 (46725664..46729211, complement) Build 37.2 previous assembly MGSCv37 (GCF_000001635.18) 17 NC_000083.5 (46862613..46866114, complement) Chromosome 17 - NC_000083.6 Page 6 of 8 https://www.alphaknockout.com Transcript information: This gene has 3 transcripts Gene: Gnmt ENSMUSG00000002769 Description glycine N-methyltransferase [Source:MGI Symbol;Acc:MGI:1202304] Gene Synonyms glycine N methyl transferase Location Chromosome 17: 46,725,664-46,729,168 reverse strand. GRCm38:CM001010.2 About this gene This gene has 3 transcripts (splice variants), 193 orthologues, is a member of 1 Ensembl protein family and is associated with 18 phenotypes. Transcripts Name Transcript ID bp Protein Translation ID Biotype CCDS UniProt Flags Gnmt-201 ENSMUST00000002846.8 1035 293aa ENSMUSP00000002846.8 Protein coding CCDS28838 Q9QXF8 TSL:1 GENCODE basic APPRIS P1 Gnmt-202 ENSMUST00000147112.1 855 No protein - Retained intron - - TSL:2 Gnmt-203 ENSMUST00000233086.1 554 No protein - lncRNA - - - 23.50 kb Forward strand 46.720Mb 46.725Mb 46.730Mb 46.735Mb Genes Pex6-203 >retained intron (Comprehensive set... Pex6-201 >protein coding Pex6-202 >lncRNA Pex6-204 >retained intron Contigs < CT030702.11 Genes (Comprehensive set... < Gnmt-201protein coding < Cnpy3-203nonsense mediated decay < Gnmt-202retained intron < Cnpy3-201protein coding < Gnmt-203lncRNA < Cnpy3-204retained intron Regulatory Build 46.720Mb 46.725Mb 46.730Mb 46.735Mb Reverse strand 23.50 kb Regulation Legend CTCF Enhancer Open Chromatin Promoter Promoter Flank Gene Legend Protein Coding merged Ensembl/Havana Non-Protein Coding RNA gene processed transcript Page 7 of 8 https://www.alphaknockout.com Transcript: ENSMUST00000002846 < Gnmt-201protein coding Reverse strand 3.50 kb ENSMUSP00000002... PDB-ENSP mappings Superfamily S-adenosyl-L-methionine-dependent methyltransferase Pfam Methyltransferase domain PROSITE profiles Glycine/Sarcosine N-methyltransferase PIRSF Glycine/Sarcosine N-methyltransferase PANTHER Glycine/Sarcosine N-methyltransferase Gene3D 3.30.46.10 3.40.50.150 CDD cd02440 All sequence SNPs/i... Sequence variants (dbSNP and all other sources) Variant Legend stop gained missense variant synonymous variant Scale bar 0 40 80 120 160 200 240 293 We wish to acknowledge the following valuable scientific information resources: Ensembl, MGI, NCBI, UCSC. Page 8 of 8.
Load more

Recommended publications
  • GNMT Expression Increases Hepatic Folate Contents and Folate-Dependent Methionine Synthase-Mediated Homocysteine Remethylation
    GNMT Expression Increases Hepatic Folate Contents and Folate-Dependent Methionine Synthase-Mediated Homocysteine Remethylation Yi-Cheng Wang,1 Yi-Ming Chen,2* Yan-Jun Lin,1 Shih-Ping Liu,2 and En-Pei Isabel Chiang1 1Department of Food Science and Biotechnology, National Chung Hsing University, Taichung, Taiwan, R.O.C; 2Institute of Microbiology and Immunology, National Yang-Ming University, Taipei, Taiwan, R.O.C. Glycine N-methyltransferase (GNMT) is a major hepatic enzyme that converts S-adenosylmethionine to S-adenosylhomocys- teine while generating sarcosine from glycine, hence it can regulate mediating methyl group availability in mammalian cells. GNMT is also a major hepatic folate binding protein that binds to, and, subsequently, may be inhibited by 5-methyltetrafolate. GNMT is commonly diminished in human hepatoma; yet its role in cellular folate metabolism, in tumorigenesis and antifolate ther- apies, is not understood completely. In the present study, we investigated the impacts of GNMT expression on cell growth, folate status, methylfolate-dependent reactions and antifolate cytotoxicity. GNMT–diminished hepatoma cell lines transfected with GNMT were cultured under folate abundance or restriction. Folate-dependent homocysteine remethylation fluxes were investi- gated using stable isotopic tracers and gas chromatography/mass spectrometry. Folate status was compared between wild-type (WT), GNMT transgenic (GNMTtg ) and GNMT knockout (GNMTko ) mice. In the cell model, GNMT expression increased folate con- centration, induced folate-dependent homocysteine remethylation, and reduced antifolate methotrexate cytotoxicity. In the mouse models, GNMTtg had increased hepatic folate significantly, whereas GNMTko had reduced folate. Liver folate levels corre- lated well with GNMT expressions (r = 0.53, P = 0.002); and methionine synthase expression was reduced significantly in GNMTko, demonstrating impaired methylfolate-dependent metabolism by GNMT deletion.
    [Show full text]
  • GNMT: a Multifaceted Suppressor of Hepatocarcinogenesis
    SImile et al. Hepatoma Res 2021;7:35 Hepatoma Research DOI: 10.20517/2394-5079.2020.162 Review Open Access GNMT: a multifaceted suppressor of hepatocarcinogenesis Maria M. SImile, Claudio F. Feo, Diego F. Calvisi, Rosa M. Pascale, Francesco Feo Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari 07100, Italy. Correspondence to: Prof. Rosa M. Pascale, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Via P Manzella, 4 07100, Sassari 07100, Italy. E-mail: [email protected] How to cite this article: SImile MM, Feo CF, Calvisi DF, Pascale RM, Feo F. GNMT: a multifaceted suppressor of hepatocarcinogenesis. Hepatoma Res 2021;7:35. https://dx.doi.org/10.20517/2394-5079.2020.162 Received: 18 Dec 2020 First Decision: 19 Jan 2021 Revised: 28 Jan 2021 Accepted: 19 Feb 2021 Published: 8 May 2021 Academic Editors: Orlando Musso, Giuliano Ramadori Copy Editor: Xi-Jun Chen Production Editor: Xi-Jun Chen Abstract Glycine N-methyltransferase (GNMT) exerts a pivotal role in the methionine cycle and, consequently, contributes to the control of methylation reactions, and purine and pyrimidine synthesis. Numerous observations indicate that GNMT is a tumor suppressor gene, but the molecular mechanisms of its suppressive action have only been partially unraveled to date. Present knowledge indicates that GNMT acts through both epigenetic and genetic mechanisms. Among them are the decrease of AKT signaling through the inhibition of the RAPTOR/mTOR complex and the interaction of GNMT with the PTEN inhibitor, PREX2. Furthermore, GNMT is a polycyclic aromatic hydrocarbon-binding protein and a mediator of the induction, by polycyclic hydrocarbons of the cytochrome P450- 1A1 gene, whose polymorphism is involved in favoring different types of cancers.
    [Show full text]
  • GNMT Gene Glycine N-Methyltransferase
    GNMT gene glycine N-methyltransferase Normal Function The GNMT gene provides instructions for producing the enzyme glycine N- methyltransferase. This enzyme is involved in a multistep process that breaks down the protein building block (amino acid) methionine. Specifically, glycine N-methyltransferase starts a reaction that converts the compounds glycine and S-adenosylmethionine (also called AdoMet) to N-methylglycine and S-adenosylhomocysteine (also called AdoHcy). This reaction also helps to control the relative amounts of AdoMet and AdoHcy. The AdoMet to AdoHcy ratio is important in many body processes, including the regulation of other genes by the addition of methyl groups, consisting of one carbon atom and three hydrogen atoms (methylation). Methylation is important in many cellular functions. These include determining whether the instructions in a particular segment of DNA are carried out, regulating reactions involving proteins and lipids, and controlling the processing of chemicals that relay signals in the nervous system (neurotransmitters). The glycine N-methyltransferase enzyme is also involved in processing toxic compounds in the liver. Health Conditions Related to Genetic Changes Hypermethioninemia At least six variants (also called mutations) in the GNMT gene have been described in individuals with hypermethioninemia, which is characterized by an excess of methionine in the blood. Most of these variants substitute one amino acid for another in the N- methyltransferase enzyme, which reduces the enzyme's function. The reduced glycine N-methyltransferase activity resulting from GNMT gene variants impairs the breakdown of methionine, causing it to build up in the blood. Excess methionine can result in neurological problems and other signs and symptoms in some individuals with hypermethioninemia.
    [Show full text]
  • In Mouse Promoter Regions Demonstrating Tissue-Specific Gene Expression
    Downloaded from genome.cshlp.org on September 25, 2021 - Published by Cold Spring Harbor Laboratory Press Methods DNA methylation profile of tissue-dependent and differentially methylated regions (T-DMRs) in mouse promoter regions demonstrating tissue-specific gene expression Shintaro Yagi,1 Keiji Hirabayashi,1 Shinya Sato,1 Wei Li,2 Yoko Takahashi,1 Tsutomu Hirakawa,1 Guoying Wu,1 Naoko Hattori,1 Naka Hattori,1 Jun Ohgane,1 Satoshi Tanaka,1 X. Shirley Liu,3 and Kunio Shiota1,4,5 1Laboratory of Cellular Biochemistry, Department of Animal Resource Sciences/Veterinary Medical Sciences, The University of Tokyo, Tokyo 113-8657, Japan; 2Division of Biostatistics, Dan L. Duncan Cancer Center, Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas 77030, USA; 3Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard School of Public Health, Boston, Massachusetts 02115, USA; 4National Institute of Advanced Industrial Science and Technology, Tsukuba, Ibaraki 305-8561, Japan DNA methylation constitutes an important epigenetic regulation mechanism in many eukaryotes, although the extent of DNA methylation in the regulation of gene expression in the mammalian genome is poorly understood. We developed D-REAM, a genome-wide DNA methylation analysis method for tissue-dependent and differentially methylated region (T-DMR) profiling with restriction tag-mediated amplification in mouse tissues and cells. Using a mouse promoter tiling array covering a region from −6 to 2.5 kb (∼30,000 transcription start sites), we found that over 3000 T-DMRs are hypomethylated in liver compared to cerebrum. The DNA methylation profile of liver was distinct from that of kidney and spleen.
    [Show full text]
  • Glycine N-Methyltransferase Tumor Susceptibility Gene in the Benzo(A)Pyrene- Detoxification Pathway
    [CANCER RESEARCH 64, 3617–3623, May 15, 2004] Glycine N-Methyltransferase Tumor Susceptibility Gene in the Benzo(a)pyrene- Detoxification Pathway Shih-Yin Chen,1 Jane-Ru Vivan Lin,1 Ramalakshmi Darbha,2 Pinpin Lin,3 Tsung-Yun Liu,4 and Yi-Ming Arthur Chen1 1Division of Preventive Medicine, Institute of Public Health, and AIDS Prevention and Research Centre, National Yang-Ming University, Taipei, Taiwan, Republic of China; 2Biomolecular Structure Section, Macromolecular Crystallography Laboratory, National Cancer Institute-Frederick, Frederick, Maryland; 3Institute of Toxicology, Chung-Shan Medical University, Taichung, Taiwan, Republic of China; and 4Department of Medical Research, Taipei Veterans General Hospital, Taiwan, Republic of China ABSTRACT and characterized its polymorphism (10, 11). Genotypic analyses of several human GNMT gene polymorphisms showed a loss of het- Glycine N-methyltransferase (GNMT) affects genetic stability by (a) erozygosity in 36–47% of the genetic markers in hepatocellular regulating the ratio of S-adenosylmethionine to S-adenosylhomocystine carcinoma tissues (11). In this study, we evaluated the effects of and (b) binding to folate. Based on the identification of GNMT asa4S polyaromatic hydrocarbon-binding protein, we used liver cancer cell lines GNMT on liver cells treated with BaP in a transient transfection that expressed GNMT either transiently or stably in cDNA transfections system or with stably expressed clones, based on the identification of to analyze the role of GNMT in the benzo(a)pyrene (BaP) detoxification GNMT asa4Spolycyclic aromatic hydrocarbon-binding protein pathway. Results from an indirect immunofluorescent antibody assay (12). We also used automated docking with a Lamarckian genetic showed that GNMT was expressed in cell cytoplasm before BaP treatment algorithm (LGA) to elucidate GNMT-BaP interaction.
    [Show full text]
  • Glycine-N-Methyltransferase (GNMT) for Use in Treatment Or Prevention of a Disease Caused by Aflatoxin B1 (AFB1)
    (19) TZZ __¥_T (11) EP 2 471 913 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 04.07.2012 Bulletin 2012/27 C12N 15/00 (2006.01) A01K 67/00 (2006.01) A23L 1/015 (2006.01) (21) Application number: 12159907.0 (22) Date of filing: 20.02.2008 (84) Designated Contracting States: • Liu, Shih-Ping AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 112 Taipai City (TW) HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR (74) Representative: TER MEER - STEINMEISTER & PARTNER GbR (30) Priority: 01.08.2007 US 832304 Patentanwälte Mauerkircherstrasse 45 (62) Document number(s) of the earlier application(s) in 81679 München (DE) accordance with Art. 76 EPC: 08003124.8 / 2 020 443 Remarks: This application was filed on 16-03-2012 as a (71) Applicant: National Yang-Ming University divisional application to the application mentioned Taipei City 112 (TW) under INID code 62. (72) Inventors: • Chen, Yi-Ming 112 Taipai City (TW) (54) Glycine-N-methyltransferase (GNMT) for use in treatment or prevention of a disease caused by aflatoxin B1 (AFB1) (57) The present invention relates to the use of Glycine N-methyltransferase (GNMT) or plasmid including GNMT in the treatment or prevention of a disease caused by aflatoxin B1 (AFB 1). EP 2 471 913 A1 Printed by Jouve, 75001 PARIS (FR) EP 2 471 913 A1 Description FIELD OF THE INVENTION 5 [0001] The present invention relates to Glycine N-methyltransferase (GNMT) animal model and use thereof.
    [Show full text]
  • Chromatin Accessibility Analysis Uncovers Regulatory Element Landscape in Prostate Cancer Progression Joonas Uusi-Mäkelä1,2*
    bioRxiv preprint doi: https://doi.org/10.1101/2020.09.08.287268; this version posted September 9, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Chromatin accessibility analysis uncovers regulatory element landscape in prostate cancer progression Joonas Uusi-Mäkelä1,2*, Ebrahim Afyounian1,2*, Francesco Tabaro1,2*, Tomi Hakkinen1,2*, Alessandro Lussana1,2, Anastasia Shcherban1,2, Matti Annala1,2, Riikka Nurminen1,2, Kati Kivinummi1,2, Teuvo L.J. Tammela1,2,3, Alfonso Urbanucci4, Leena Latonen5, Juha Kesseli1,2, Kirsi J. Granberg1,2, Tapio Visakorpi1,2,6, Matti Nykter1,2✦ 1 Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland 2 Tays Cancer Center, Tampere University Hospital, Tampere, Finland 3 Department of Urology, Tampere University Hospital, Tampere, Finland 4 Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway 5 Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland 6 Fimlab Laboratories Ltd, Tampere, Finland *These authors contributed equally. ✦Corresponding author 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.09.08.287268; this version posted September 9, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Abstract Aberrant oncogene functions and structural variation alter the chromatin structure in cancer cells.
    [Show full text]
  • Genomic Structure, Expression, and Chromosomal Localization of the Human Glycine N-Methyltransferase Gene Yi-Ming A
    Genomics 66, 43–47 (2000) doi:10.1006/geno.2000.6188, available online at http://www.idealibrary.com on Genomic Structure, Expression, and Chromosomal Localization of the Human Glycine N-Methyltransferase Gene Yi-Ming A. Chen,*,1 Li-Ying Chen,* Fen-Hwa Wong,* Cheng-Ming Lee,* Tai-Jay Chang,*,† and Teresa L. Yang-Feng‡ *Division of Preventive Medicine, Institute of Public Health, School of Medicine, National Yang-Ming University, Taipei, Taiwan 112, R.O.C.; †Department of Medical Research, Taipei Veterans General Hospital, Taiwan 112, R.O.C.; and ‡Department of Genetics, Yale University School of Medicine, New Haven, Connecticut 06511 Received December 6, 1999; accepted March 7, 2000 GNMT gene has been isolated and characterized The glycine N-methyltransferase (GNMT) gene en- (Ogawa et al., 1987). codes a protein that not only acts as an enzyme to Previously, the expression level of GNMT was found regulate the ratio of S-adenosylmethionine to S-adeno- to be diminished in both human hepatocellular carci- sylhomocysteine, but also participates in the detoxifi- noma (HCC) tissues and cell lines. Subsequently, the cation pathway in liver cells. Previously, we reported cDNA of human GNMT was isolated from a Taiwanese that the expression level of GNMT was diminished in liver cDNA library (Chen et al., 1998). To elucidate the human hepatocellular carcinoma. In this study, the mechanism of gene control and its association with human GNMT gene was cloned and characterized. It HCC, the GNMT gene was isolated, and its structure contains six exons and spans about 10 kb. Instead of a and chromosomal localization were analyzed in this TATA box, it has a transcriptional initiator located 801 study.
    [Show full text]
  • Epigenetic Silencing of GNMT Gene in Pancreatic Adenocarcinoma
    CANCER GENOMICS & PROTEOMICS 12 : 21-30 (2015) Epigenetic Silencing of GNMT Gene in Pancreatic Adenocarcinoma ANCA BOTEZATU 1, CORALIA BLEOTU 2, ANCA NASTASE 3, GABRIELA ANTON 1, NICOLAE BACALBASA 4, DAN DUDA 5, SIMONA OLIMPIA DIMA 3 and IRINEL POPESCU 3 1Viral Genetic Engineering Laboratory, Romanian Academy “Stefan S. Nicolau”Virology Institute, Bucharest, Romania; 2Antiviral Therapy Engineering Laboratory, Romanian Academy “Stefan S. Nicolau”Virology Institute, Bucharest, Romania; 3Center of General Surgery and Liver Transplantation “Dan Setlacec”, Fundeni Clinical Institute, Bucharest, Romania; 4“Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania; 5Edwin L. Steele Laboratory for Tumor Biology, Charlestown, MA, U.S.A. Abstract. Background/Aim: Although pancreatic ductal Conclusion: Collectively, these data indicate that GNMT is adenocarcinoma (PDAC) remains a major challenge for aberrantly methylated in PDAC representing, thus, a therapy, biomarkers for early detection are lacking. potential major mechanism for gene silencing. Methylation Epigenetic silencing of tumor suppressor genes is a of GNMT gene is directly correlated with disease stage and majorcontributor to neoplastic transformation. The aim of with tumor grade indicating that these epigenetic effects may this study was to identify new factors involved in PDAC be important regulators of PDAC progression. progression. The GNMT gene possesses CpG islands in the promoter region and is important in methyl-group Pancreatic ductal adenocarcinoma (PDAC) is a malignant
    [Show full text]
  • DMD #46953 1 Human Liver Methionine Cycle: MAT1A And
    DMD Fast Forward. Published on July 17, 2012 as DOI: 10.1124/dmd.112.046953 DMD ThisFast article Forward. has not been Published copyedited andon formatted.July 17, The 2012 final asversion doi:10.1124/dmd.112.046953 may differ from this version. DMD #46953 1 Human Liver Methionine Cycle: MAT1A and GNMT Gene Resequencing, Functional Genomics and Hepatic Genotype-Phenotype Correlation Yuan Ji, Kendra K.S. Nordgren, Yubo Chai, Scott J. Hebbring, Gregory D. Jenkins, Ryan P. Abo, Yi Peng, Linda L. Pelleymounter, Irene Moon, Bruce W. Eckloff, Xiaoshan Chai, Jianping Zhang, Brooke L. Fridley, Vivien C. Yee, Eric D. Wieben and Richard M. Weinshilboum Downloaded from dmd.aspetjournals.org From the Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics (Y.J., K.K.S.N., Y.C., S.H., R.A., L.L.P., I.M., X.C., J.Z., R.M.W.), Division of Biomedical Statistical and Informatics, Department of Health Sciences Research at ASPET Journals on October 1, 2021 (G.D.J., B.L.F.), Department of Biochemistry and Molecular Biology (B.W.E., E.D.W.), Mayo Clinic, Rochester, MN; Department of Biochemistry, Case Western Reserve University, Cleveland, OH (Y.P. and V.C.Y.); College of Pharmacy, Jinan University, Guangzhou, PR China (J.Z.) Copyright 2012 by the American Society for Pharmacology and Experimental Therapeutics. DMD Fast Forward. Published on July 17, 2012 as DOI: 10.1124/dmd.112.046953 This article has not been copyedited and formatted. The final version may differ from this version. DMD #46953 2 Running title: MAT1A and GNMT Sequence Variation and Functional Genomics Address correspondence and reprint requests to Richard M.
    [Show full text]
  • Temporal Linkage Between the Phenotypic and Genomic Responses to Caloric Restriction
    Temporal linkage between the phenotypic and genomic responses to caloric restriction Joseph M. Dhahbi*†, Hyon-Jeen Kim†‡, Patricia L. Mote†, Robert J. Beaver§, and Stephen R. Spindler†¶ *BioMarker Pharmaceuticals, Incorporated, 900 East Hamilton Avenue, Campbell, CA 95008; and Departments of †Biochemistry and §Statistics, University of California, Riverside, CA 92521 Edited by Cynthia J. Kenyon, University of California, San Francisco, CA, and approved January 26, 2004 (received for review August 18, 2003) Caloric restriction (CR), the consumption of fewer calories while 72% of the genomic effects of LT-CR. The results closely link the avoiding malnutrition, decelerates the rate of aging and the devel- lifespan and genomic effects of CR, suggesting a cause-and-effect opment of age-related diseases. CR has been viewed as less effective relationship. in older animals and as acting incrementally to slow or prevent age-related changes in gene expression. Here we demonstrate that Materials and Methods CR initiated in 19-month-old mice begins within 2 months to increase Study Design. Male mice of the long-lived F1 hybrid strain B6C3F1 the mean time to death by 42% and increase mean and maximum were purchased (Harlan Breeders, Indianapolis). On arrival, mice .were housed four per cage and fed ad libitum a nonpurified diet (no ,(0.000056 ؍ and 6.0 months (P (0.000017 ؍ lifespans by 4.7 (P respectively. The rate of age-associated mortality was decreased 5001, Purina). For the survival study, 19-month-old mice were 3.1-fold. Between the first and second breakpoints in the CR survival randomly assigned to control and CR groups of 60 each.
    [Show full text]
  • Arxiv:2108.10808V1 [Cs.LG] 24 Aug 2021 the Degree of Master of Philosophy in the Department of Electronic and Computer Engineering
    Greenformers: Improving Computation and Memory Efficiency in Transformer Models via Low-Rank Approximation by SAMUEL CAHYAWIJAYA A Thesis Submitted to The Hong Kong University of Science and Technology in Partial Fulfillment of the Requirements for arXiv:2108.10808v1 [cs.LG] 24 Aug 2021 the Degree of Master of Philosophy in the Department of Electronic and Computer Engineering August 2021, Hong Kong Authorization I hereby declare that I am the sole author of the thesis. I authorize the Hong Kong University of Science and Technology to lend this thesis to other institutions or individuals for the purpose of scholarly research. I further authorize the Hong Kong University of Science and Technology to reproduce the thesis by photocopying or by other means, in total or in part, at the request of other institutions or individuals for the purpose of scholarly research. SAMUEL CAHYAWIJAYA 24 August 2021 ii Greenformers: Improving Computation and Memory Efficiency in Transformer Models via Low-Rank Approximation by Samuel Cahyawijaya This is to certify that I have examined the above M.Phil. thesis and have found that it is complete and satisfactory in all respects, and that any and all revisions required by the thesis examination committee have been made. Prof. Pascale FUNG, Thesis Supervisor Prof. Andrew Wing On POON, Head of Department Thesis Examination Committee 1. Prof. Stuart GIETEL-BASTEN Division of Social Science 2. Prof. Pascale FUNG Department of Electronic and Computer Engineering 3. Prof. Qifeng CHEN Department of Electronic and Computer Engineering Department of Electronic and Computer Engineering August 2021 iii Acknowledgments I would never have completed this work without the help from many people.
    [Show full text]